Almirall, S.A.
General ticker "LBTSF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $2.4B (TTM average)
Almirall, S.A. follows the US Stock Market performance with the rate: 44.5%.
Estimated limits based on current volatility of 0.0%: low 13.36$, high 13.36$
Factors to consider:
- Company pays dividends (irregularly): last record date 2025-05-16, amount 0.21$ (Y1.57%)
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [7.01$, 12.14$]
- 2025-12-31 to 2026-12-31 estimated range: [6.73$, 11.80$]
Financial Metrics affecting the LBTSF estimates:
- Positive: with PPE of 181.7 at the end of fiscal year the price was very low
- Positive: -3.60 < Operating profit margin, % of 3.66
- Negative: negative Industry operating cash flow (median)
- Positive: 41.86 < Shareholder equity ratio, % of 62.10 <= 63.39
- Negative: 0.79 < Interest expense per share per price, % of 0.82
- Negative: Investing cash flow per share per price, % of -6.79 <= -4.48
- Positive: 6.82 < Operating cash flow per share per price, % of 7.80
- Negative: Industry earnings per price (median), % of 0 <= 0
Short-term LBTSF quotes
Long-term LBTSF plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | €863.25MM | €894.52MM | €985.72MM |
| Operating Expenses | €816.38MM | €899.78MM | €949.63MM |
| Operating Income | €46.87MM | €-5.26MM | €36.09MM |
| Non-Operating Income | €-15.84MM | €-11.93MM | €-9.59MM |
| Interest Expense | €7.44MM | €7.21MM | €17.00MM |
| R&D Expense | €64.28MM | €66.91MM | €79.00MM |
| Income(Loss) | €31.03MM | €-17.19MM | €26.50MM |
| Taxes | €0.00MM | €21.28MM | €0.00MM |
| Profit(Loss)* | €4.28MM | €-38.47MM | €10.15MM |
| Stockholders Equity | €1,318.71MM | €1,463.40MM | €1,488.38MM |
| Inventory | €129.95MM | €167.37MM | €171.69MM |
| Assets | €2,147.69MM | €2,374.99MM | €2,396.66MM |
| Operating Cash Flow | €155.10MM | €93.48MM | €160.77MM |
| Capital expenditure | €116.48MM | €159.30MM | €161.43MM |
| Investing Cash Flow | €-68.54MM | €-122.56MM | €-140.04MM |
| Financing Cash Flow | €-45.12MM | €168.21MM | €-31.58MM |
| Earnings Per Share** | €0.02 | €-0.20 | €0.04 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.